Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Eligibility Criteria

• * Male and female subjects age 18 or older
• * Clinical diagnosis of gout according to the 2015 ACR/EULAR Gout Classification Criteria:
• * Confirmation of a gout flare in the target joint that began within 96 hours prior to the Screening/Baseline Visit
• * Provide written informed consent and understand and comply with all trial requirements
• * Presence of any palpable and visible tophi by physical examination
• * Has ≥ 4 joints with an acute gout flare at Screening/Baseline
• * Presence of active rheumatoid arthritis or other acute inflammatory arthritis
• * Evidence/suspicion of infectious/septic arthritis
• * Clinically significant general pain or non-gout-related joint pain that would interfere with the subject's ability to accurately assess pain in the target joint
• * Known diagnosis of chronic kidney disease or known history of renal impairment
• * Positive test for severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection, if tested, within 4 weeks of the Screening/Baseline
• * Active malignancy or recent malignancy with any systemic anti-cancer treatment
• * Has a hypersensitivity or allergy to OLT1177® or other drugs in its class
• * Hypersensitivity or allergy to paracetamol/acetaminophen
• * Use of any prohibited concomitant medications/therapies over the periods defined in the protocol or planned use of any prohibited concomitant medications/therapies during the Treatment Period (including the use of paracetamol/acetaminophen within 4 hours prior to the Screening/Baseline Visit or other pain medications within 12 hours prior to the Screening/ Baseline Visit
• * Use of any product containing paracetamol/acetaminophen within 4 hours prior to the Screening/Baseline Visit or planned use during the Treatment Period (with the exception of study-provided Rescue Medication \[paracetamol/acetaminophen\], which is permitted after completion of the first target joint pain assessment on Study Day 4